The 12 Slide Biotech Pitch Deck Template​

Slide 1: Elevator Pitch (Problem + Solution)

Objective:

Capture investor interest within seconds by clearly stating the problem and your unique solution.

Structure:

1. The Problem (Name the Enemy)
   • A concise, high-impact statement about the problem in the biotech or healthcare industry.
   • Example: “Despite decades of research, over 70% of rare diseases still have no approved treatment, leaving millions without hope.”
2. Your Solution (What You Offer)
   • A clear, one-line summary of what your biotech innovation does.
   • Example: “Our gene-editing platform leverages CRISPR technology to create personalized therapies for rare genetic disorders.”
3. The Big Impact (Why It Matters)
   • A high-level, quantified benefit of your solution.
   • Example: “Our approach reduces treatment costs by 40% and speeds up clinical trials by 50%, making lifesaving drugs accessible to millions faster.”

Visuals:

• A high-quality, conceptual image (e.g., DNA sequencing, lab work, biotech innovation).
• A simple headline + subheadline with minimal text.

Slide 2: Investor Highlights

Objective:

Provide a compelling snapshot of why this investment opportunity is attractive.

Structure:

1. Market Size & Opportunity
   • Example: “$75B+ market in personalized medicine, growing at 12% CAGR.”
2. Breakthrough Technology
   • Example: “First-in-class CRISPR therapy with AI-driven target selection.”
3. Regulatory & IP Strength
   • Example: “3 patents granted, 2 pending. FDA Fast Track designation secured.”
4. Clinical or Preclinical Success
   • Example: “Preclinical studies show 90% efficacy in gene correction with no off-target effects.”
5. Experienced Leadership Team
   • Example: “Founded by leading geneticists and ex-Pfizer R&D executives.”
6. Scalability & Exit Potential
   • Example: “Strong M&A interest from major pharma players and projected IPO within 5 years.”

Visuals:

• Bullet points (clean and to the point).
• Market size and growth trend chart.
• Logos of strategic partners or endorsements.

Slide 3: The Problem & Urgency

Objective:

Highlight the pain points and create a sense of urgency around the problem.

Structure:

1. What’s Broken? (The Status Quo)
   • Example: “Current treatments for rare genetic disorders are either non-existent or prohibitively expensive, costing over $500K per patient annually.”
2. The Human & Economic Toll
   • Example: “Patients endure years of misdiagnosis, ineffective treatments, and deteriorating quality of life. Healthcare systems spend billions on managing symptoms instead of treating the root cause.”
3. Why Now? (The Urgency Factor)
   • Example: “Recent advancements in gene therapy and AI-driven drug discovery mean we finally have the tools to tackle these diseases effectively.”

Visuals:

• A patient-centric image to create emotional connection.
• Data visualization showing increasing prevalence of rare diseases or the economic burden.

Slide 4: Market Opportunity

Objective:

Demonstrate the scale of the opportunity and the potential for high returns.

Structure:

1. Total Addressable Market (TAM)
   • Example: “The global market for genetic therapies is projected to reach $150B by 2030.”
2. Serviceable Available Market (SAM)
   • Example: “We are initially targeting the $25B rare genetic disease market, growing at 18% CAGR.”
3. Serviceable Obtainable Market (SOM)
   • Example: “By focusing on the top 3 untapped genetic conditions, we estimate a $5B+ revenue opportunity within the next 5 years.”
4. Industry Trends Favoring Growth
   • Example: “Regulatory bodies are accelerating approval pathways for precision medicine, and major pharma companies are increasing M&A activity in biotech.”

Visuals:

• A TAM/SAM/SOM pie chart to visually depict the market segmentation.
• A line graph showcasing market growth trends.

Slide 5: The Science & Unique Solution

Objective:

Explain your biotech innovation in a way that is clear, yet compelling.

Structure:

1. How It Works (Simplified Scientific Explanation)
   • Example: “Our proprietary AI-driven platform identifies genetic mutations with 99% accuracy and applies CRISPR edits with unparalleled precision.”
2. Key Differentiators (What Makes It Special?)
   • Higher efficacy
   • Faster development timeline
   • Lower costs compared to existing therapies
3. Scientific Validation & Early Results
   • Example: “In vivo studies show 90% success in correcting genetic mutations, with minimal immune response.”
4. Intellectual Property & Competitive Edge
   • Example: “We hold exclusive patents on our AI-driven target identification and delivery mechanism.”

Visuals:

• A simple before & after graphic explaining how the technology works.
• Comparison table showing how this solution is superior to competitors.

Slide 6: Competitive Advantage & IP Strategy

Objective:

Show why competitors cannot easily replicate what you’re doing.

Structure:

1. How You Compare to the Competition
   • Example: “Unlike conventional gene therapies that struggle with off-target effects, our AI-driven approach reduces errors by 80%.”
2. Intellectual Property Protection
   • Example: “3 issued patents on delivery mechanism and gene-editing accuracy, with 2 more in process.”
3. Barriers to Entry
   • Proprietary data & AI models trained on unique datasets.
   • Established partnerships with top-tier research institutions.
   • Regulatory advantages (e.g., Fast Track designation from FDA).
4. Competitive Threats & How You Mitigate Them
   • Competitor X: “Focused on different genetic indications, does not address the same disease areas.”
   • Competitor Y: “Limited by outdated delivery methods, struggles with immune response issues.”

Visuals:

• Competitive landscape matrix (your company vs. competitors).
• IP strategy roadmap showcasing issued patents and future filings.

Slide 7: Business & Revenue Model

Objective:

Demonstrate how the business will generate revenue and achieve financial sustainability.

Structure:

1. Revenue Streams
   • Direct Drug Sales: Pricing model for therapies.
   • Licensing & Royalties: Partnering with big pharma for commercialization.
   • Government Grants & Research Funding: Non-dilutive funding opportunities.
   • Strategic Partnerships & Joint Ventures: Co-developing or co-marketing treatments.
2. Pricing & Reimbursement Strategy
   • Example: “We will work with insurers to ensure broad market adoption and reimbursement approval, similar to how leading gene therapies have been integrated into healthcare systems.”
3. Scalability & Growth Plan
   • Expansion into additional indications beyond the initial target disease.
   • Global market expansion strategy.
4. Projected Financial Growth
   • Estimated revenue in 3-5 years, based on licensing deals, product launch timelines, and market penetration.

Visuals:

• Revenue model diagram showing various income streams.
• Projected revenue growth chart with 3-5 year forecast.

Slide 8: Clinical Trials & Regulatory Pathway

Objective:

Showcase your regulatory strategy and how you mitigate the risk of clinical development.

Structure:

1. Clinical Trial Status & Roadmap
   • Example:
     
     • Preclinical – Completed animal studies with strong efficacy.
     • Phase 1 – Demonstrating safety in humans (projected start: Q3 2025).
     • Phase 2 – Proving efficacy (projected start: Q2 2026).
     • Phase 3 – Large-scale trials and FDA submission (2028).
2. Regulatory Milestones & FDA Strategy
   • Fast Track, Breakthrough Therapy, or Orphan Drug Designation.
   • Example: “Our therapy qualifies for Orphan Drug Designation, which grants market exclusivity for 7 years post-approval.”
3. Risk Mitigation Plan
   • Strategies to de-risk clinical trials (e.g., strong preclinical data, collaboration with regulatory consultants, adaptive trial designs).
   • Example: “We have secured advisory meetings with the FDA to ensure a clear regulatory pathway.”

Visuals:

• Timeline of clinical development & approval milestones.
• Regulatory designation benefits table (e.g., Fast Track = shorter review times).

Slide 9: Traction & Milestones

Objective:

Provide proof that the company is making significant progress.

Structure:

1. Major Achievements to Date
   • Example:
     
     • “Raised $5M in non-dilutive NIH funding for preclinical development.”
     • “Completed animal studies showing 90% gene correction success rate.”
     • “Signed partnership with top-tier research institution for clinical trial execution.”
2. Strategic Partnerships & Collaborations
   • Big pharma partnerships.
   • University & research collaborations.
   • Government agency involvement.
3. Upcoming Milestones (Next 12-24 Months)
   • Example:
     
     • “IND filing submission with the FDA (Q4 2025).”
     • “Completion of Phase 1 trial (Q2 2026).”

Visuals:

• Timeline with key milestones & upcoming goals.
• Logos of research partners, investors, and collaborators.

Slide 10: Go-to-Market Strategy

Objective:

Explain how the company will successfully commercialize its biotech innovation.

Structure:

1. Initial Market Entry Strategy
   • Direct Sales to Specialty Clinics: Targeting hospitals and clinics specializing in genetic disorders.
   • Pharmaceutical Partnerships: Licensing deals with pharma companies for late-stage clinical development and sales.
2. Scaling & Market Expansion
   • Expanding into additional indications (e.g., from rare diseases to broader applications).
   • Global expansion strategy (e.g., “Phase 3 trials in both U.S. and Europe to ensure international market access.”)
3. Regulatory & Reimbursement Strategy
   • Working with payers and insurers to ensure coverage & reimbursement.
   • Example: “We will work with Medicare, Medicaid, and private insurers to secure market access post-approval.”
4. Market Adoption & Customer Targeting
   • Key opinion leaders (KOLs), hospital adoption programs, and physician education.

Visuals:

• Go-to-market roadmap (initial launch, expansion phases).
• Graph showing projected market penetration & revenue growth.

Slide 11: The Team

Objective:

Demonstrate that you have a world-class team capable of executing the vision.

Structure:

1. Founders & Leadership Team
   • Brief, impactful bios highlighting relevant experience.
   • Example:
     
     • Dr. Jane Smith (CEO) – 20+ years in biotech leadership, ex-Pfizer R&D.
     • Dr. Mark Johnson (CSO) – Pioneer in gene editing, published 50+ papers in Nature & Science.
2. Scientific & Advisory Board
   • Highlight leading biotech investors, regulatory experts, and industry veterans supporting the company.
   • Example: “Our advisory board includes former FDA regulatory officers and leading oncologists in gene therapy.”
3. Hiring Plan & Talent Strategy
   • Roles needed for scaling (e.g., regulatory affairs, commercialization team).

Visuals:

• Headshots + short bios (1-2 lines per person).
• Logos of past companies they’ve worked at (Pfizer, NIH, etc.).

Slide 12: Funding Ask & Use of Funds

Objective:

Clearly state how much capital you are raising and how it will be deployed.

Structure:

1. Funding Ask & Stage
   • Example:
     
     • “We are raising $20M in Series A funding to advance our lead therapy through Phase 1 clinical trials.”
2. Allocation of Funds
   • Example:
     
     • 50% – Clinical Trials (Phase 1 & regulatory approvals)
     • 25% – R&D & Pipeline Expansion
     • 15% – Hiring & Infrastructure
     • 10% – IP & Legal Costs
3. Expected Runway & Next Milestone
   • How long the funding will last (e.g., “This will provide a 24-month runway, covering completion of Phase 1 trials and FDA filing.”).
4. Exit Strategy & Investor ROI
   • Acquisition potential (M&A with major biotech companies).
   • IPO strategy for long-term scaling.

Visuals:

• Pie chart of fund allocation.
• Timeline of funding milestones (this raise → next round).